UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Identification of druggable cancer driver genes amplified across TCGA datasets

PloS one, 2014-05, Vol.9 (5), p.e98293

2014

Volltextzugriff (PDF)

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Clinical cancer research, 2019-12, Vol.25 (23), p.7175-7188

2019

Volltextzugriff (PDF)

Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive genes in breast cancer samples from TCGA

PloS one, 2019-01, Vol.14 (1), p.e0210910-e0210910

2019

Volltextzugriff (PDF)

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

PloS one, 2022-07, Vol.17 (7), p.e0268244-e0268244

2022

Volltextzugriff (PDF)

High-throughput assays for promiscuous inhibitors

Nature chemical biology, 2005-08, Vol.1 (3), p.146-148

2005

Volltextzugriff (PDF)

Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs

Journal of medicinal chemistry, 2003-10, Vol.46 (21), p.4477-4486

2003

Volltextzugriff (PDF)

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

Journal of translational medicine, 2022-03, Vol.20 (1), p.134-134, Article 134

2022

Volltextzugriff (PDF)

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

Journal of immunotherapy (1997), 2021-09, Vol.44 (7), p.264-275

2021

Volltextzugriff (PDF)

Molecular Docking and High-Throughput Screening for Novel Inhibitors of Protein Tyrosine Phosphatase-1B

Journal of medicinal chemistry, 2002-05, Vol.45 (11), p.2213-2221

2002

Volltextzugriff (PDF)

Epilogue to the Gerald Maggiora Festschrift: a tribute to an exemplary mentor, colleague, collaborator, and innovator

Journal of computer-aided molecular design, 2022-09, Vol.36 (9), p.623-638

2022

Volltextzugriff (PDF)

3D QSAR Methods: Phase and Catalyst Compared

Journal of chemical information and modeling, 2007-05, Vol.47 (3), p.1248-1257

2007

Volltextzugriff (PDF)

Abstract 5109: Identical cancer cell lines from Sanger & Broad CCLE programs sometimes differ

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5109-5109

Doman, Thompson N.

2012

Volltextzugriff (PDF)

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

Oncoimmunology, 2016-07, Vol.5 (7), p.e1151595-e1151595

2016

Volltextzugriff (PDF)

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4549-4549

2018

Volltextzugriff (PDF)

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3632-3632

2018

Volltextzugriff (PDF)

Stromal-Based Signatures for the Classification of Gastric Cancer

Cancer research (Chicago, Ill.), 2016-05, Vol.76 (9), p.2573-2586

2016

Volltextzugriff (PDF)

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3945-3945

2019

Volltextzugriff (PDF)

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A160-A160

2018

Volltextzugriff (PDF)

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B108-B108

2018

Volltextzugriff (PDF)

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.583-583

2017

Volltextzugriff (PDF)

Molecular mechanics force fields for linear metallocenes

Journal of the American Chemical Society, 1992-08, Vol.114 (18), p.7264-7272

1992

Volltextzugriff (PDF)

Molecular Mechanics Force Fields for Bent Metallocenes of the Type [M(Cp)2Cl2]

Journal of the American Chemical Society, 1995-02, Vol.117 (4), p.1352-1368

1995

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(40)
Dissertationen
(1)

Sprache

Englisch
(40)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Identification of druggable cancer driver genes amplified across TCGA datasets

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive genes in breast cancer samples from TCGA

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

High-throughput assays for promiscuous inhibitors

Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

Molecular Docking and High-Throughput Screening for Novel Inhibitors of Protein Tyrosine Phosphatase-1B

Epilogue to the Gerald Maggiora Festschrift: a tribute to an exemplary mentor, colleague, collaborator, and innovator

3D QSAR Methods: Phase and Catalyst Compared

Abstract 5109: Identical cancer cell lines from Sanger & Broad CCLE programs sometimes differ

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Stromal-Based Signatures for the Classification of Gastric Cancer

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

Abstract A160: Combination of necitumumab with second- or third-generation EGFR tyrosine kinase inhibitors downregulates DNA repair mechanisms and induces durable tumor remissions in xenograft NSCLC models with EGFR mutations

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Molecular mechanics force fields for linear metallocenes

Molecular Mechanics Force Fields for Bent Metallocenes of the Type [M(Cp)2Cl2]

Suchergebnisse filtern